[e-drug] RFI: Country Attitudes Toward Generic Substitution

e-drug
1

E-DRUG: RFI: Country Attitudes Toward Generic Substitution
----------------------------------------------------------

Dear E-drug colleagues,

I am a Phd student and writing a dissertation about what influences the gap
between generic and brand name market share by using country and (hopefully
if the data allows me) industry comparison.

I have been dugging the archive e-mails in e-drug and I found them really
useful because it gives me a practical guides what really happens out there.

I am particularly interested in Joel Lexchin's e-mail dated back on 3 April
1997 about drug patent law/Canadian Supreme Court (see
http://www.essentialdrugs.org/edrug/archive/199704/msg00008.php ).

Could you tell me more about the Canadian position toward generic
substitution and what your opinion about this?

I also want to ask every body where I can find resources on the attitude of
(OECD) countries toward generic substitution.

I appreciate any help on this matter.

Kind Regards,

Lenny H Pattikawa
Ph.D. Candidate
Erasmus Research Institute of Management
Erasmus University Rotterdam
Room H16-7
PO Box 1738
3000 DR Rotterdam
The Netherlands
mail pattikawa@few.eur.nl
Phone +31 10 408 1321
Fax +31 10 408 9031

[Moderator's comment: glad to see the E-drug archives
(www.essentialdrugs.org/edrug) are useful. Google has 4780 references to
"generic substitution", so there is planty of data. Does anyone know a good
review study of national policies?
WHO recommends generic substitution to all member states, not only OECD
ones! WB]

--
To send a message to E-Drug, write to: e-drug@healthnet.org
To subscribe or unsubscribe, write to: majordomo@healthnet.org
in the body of the message type: subscribe e-drug OR unsubscribe e-drug
To contact a person, send a message to: e-drug-help@healthnet.org
Information and archives: http://www.essentialdrugs.org/edrug